Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
Guoxin Zhang *Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-1996-4315
Zhen Dong *Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0001-6706-3899
Ryan C GimpleDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-7189-3243
Arthur WolinDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0003-1881-390X
Qiulian WuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-7774-9576
Zhixin QiuDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0001-7103-8004
Lisa M WoodDepartment of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-6501-5188
Jia Z ShenTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.ORCID 0000-0002-4983-2049
Li JiangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-7337-7808
Linjie ZhaoDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-3372-2873
Deguan LvDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0003-3142-9814
Briana C PragerDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0001-7173-6021
Leo J Y KimDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-1790-9136
Xiuxing WangDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0002-5993-9368
Lingdi ZhangDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-8671-1385
Ryan L AndersonDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-5040-0550
Jeffrey K MooreDepartment of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0003-3262-3248
Shideng BaoDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-4236-2662
Thomas H KellerExperimental Drug Development Centre, Agency for Science, Technology and Research, Singapore.ORCID 0000-0002-7553-6235
Grace LinExperimental Drug Development Centre, Agency for Science, Technology and Research, Singapore.ORCID 0000-0001-9222-2767
Congbao KangExperimental Drug Development Centre, Agency for Science, Technology and Research, Singapore.ORCID 0000-0002-9886-9374
Rui ZhaoDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0003-0045-2974
Heide L FordDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0002-2860-9841
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.ORCID 0000-0001-7845-5302
University of California San Diego · USUniversity of Colorado Anschutz Medical Campus · USAgency for Science, Technology and Research · SGUniversity of Colorado Denver · USCleveland Clinic Lerner College of Medicine · USDanish Cancer Society · DKSanford Burnham Prebys Medical Discovery Institute · USUniversity of Pittsburgh · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Dynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4M
Deciphering Mechanisms by which Tumor Cells Collaborate to Mediate MetastasisR01CA224867 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., LEWIS, MICHAEL T. · 2019 to 2023
$3.2M
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progressionR01CA221282 · NCI · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L., ZHAO, RUI · 2017 to 2021
$3.2M
Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8M
Functional Inhibition of Deubiquitylase HAUSP to Disrupt Glioblastoma Stem CellsR01CA184090 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG · 2015 to 2019
$1.8M
Ubiquitination and Deubiquitination of c-Myc in GlioblastomaR01NS099175 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG · 2016 to 2020
$1.7M
Glioblastoma stem cell-derived pericytes and cancer invasionR01NS091080 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI BAO, SHIDENG · 2016 to 2020
$1.7M
Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7M
Examining the EYA2/MYC axis in Group 3 MedulloblastomaR01NS108396 · NINDS · UNIVERSITY OF COLORADO DENVER · PI FORD, HEIDE L. · 2018 to 2021
$1.6M
The Unfolded Protein Response in GlioblastomaF30CA217066 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI PRAGER, BRIANA · 2017 to 2020
$195k
Epigenetic Regulation of Lipid Metabolism in Glioma Stem CellsF30CA217065 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI GIMPLE, RYAN CHRISTOPHER · 2017 to 2020
Glioblastoma ranks among the most lethal of primary brain malignancies, with glioblastoma stem cells (GSCs) at the apex of tumor cellular hierarchies. Here, to discover novel therapeutic GSC targets, we interrogated gene expression profiles from GSCs, differentiated glioblastoma cells (DGCs), and neural stem cells (NSCs), revealing EYA2 as preferentially expressed by GSCs. Targeting EYA2 impaired GSC maintenance and induced cell cycle arrest, apoptosis, and loss of self-renewal. EYA2 displayed novel localization to centrosomes in GSCs, and EYA2 tyrosine (Tyr) phosphatase activity was essential for proper mitotic spindle assembly and survival of GSCs. Inhibition of the EYA2 Tyr phosphatase activity, via genetic or pharmacological means, mimicked EYA2 loss in GSCs in vitro and extended the survival of tumor-bearing mice. Supporting the clinical relevance of these findings, EYA2 portends poor patient prognosis in glioblastoma. Collectively, our data indicate that EYA2 phosphatase function plays selective critical roles in the growth and survival of GSCs, potentially offering a high therapeutic index for EYA2 inhibitors.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. · full record | OpenQuestion